P. Cordelier

This paper develops a non-viral gene therapy, CYL-02, for pancreatic cancer, demonstrating its safety, biodistribution, and therapeutic efficacy when combined with gemcitabine.

This study shows that the minute virus of mice (MVMp) selectively targets and kills mesenchymal, basal-like pancreatic cancer cells, both in vitro and in vivo, offering a potential precision therapy for aggressive pancreatic tumors.

This study shows that Cytidine deaminase (CDA) promotes mitochondrial biogenesis and oxidative phosphorylation in pancreatic cancer cells, independent of its deaminase activity, revealing new therapeutic targets.

This study shows that Cytidine deaminase (CDA) protects pancreatic cancer cells from replication stress and contributes to resistance against DNA-targeting drugs.

This paper identifies PI3K pathway activation as a driver of metastatic progression in pancreatic cancer and shows that targeting PI3K can delay macro-metastatic evolution.

This study shows that TLR7 ligands inhibit pancreatic cancer cell growth in vitro but promote tumor growth in immunocompetent mice due to increased tumor-promoting macrophages.